IMMIX BIOPHARMA, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
IMMIX BIOPHARMA, INC. (IMMX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $1.62 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.56.
- IMMIX BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.99.
- IMMIX BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $1.33, a 31.79% decline from fiscal 2024.
- IMMIX BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $1.95, a 0.52% increase from fiscal 2023.
- IMMIX BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $1.94, a 45.86% increase from fiscal 2022.
- IMMIX BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $1.33.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.62 10-Q · filed 2026-08-07 | |||
| 2026-03-31 | $1.56 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $1.33 10-K/A · filed 2026-03-27 | |||
| 2025-09-30 | $1.33 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | $1.33 10-Q · filed 2025-08-08 | |||
| 2024-12-31 | $1.95 10-K/A · filed 2026-03-27 | |||
| 2024-09-30 | $1.95 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $1.95 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $1.99 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $1.94 10-K · filed 2025-03-25 | |||
| 2022-12-31 | $1.33 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $1.33 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $1.33 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |